Sugi Predict

Sugi Predict / Compounds / SCHEMBL1507688

SCHEMBL1507688

SCHEMBL1507688

C#Cc1cccc(Nc2ncnc3cc(OC)c(CC(N)=O)cc23)c1

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ EGFR P00533 14/20 0.71
▸ GAK O14976 3/20 0.71
▸ FBP1 P09467 2/20 0.71
▸ ALDH1A1 P00352 1/20 0.71
▸ MAPT P10636 1/20 0.71
▸ HDAC3 O15379 7/20 0.65
▸ HDAC4 P56524 7/20 0.65
▸ HDAC1 Q13547 7/20 0.65
▸ HDAC7 Q8WUI4 7/20 0.65
▸ HDAC2 Q92769 7/20 0.65
▸ HDAC10 Q969S8 7/20 0.65
▸ HDAC11 Q96DB2 7/20 0.65
▸ HDAC8 Q9BY41 7/20 0.65
▸ HDAC6 Q9UBN7 7/20 0.65
▸ HDAC9 Q9UKV0 7/20 0.65
▸ HDAC5 Q9UQL6 7/20 0.65
▸ ERBB2 P04626 8/20 0.64
▸ RIPK2 O43353 2/20 0.63
▸ BUB1 O43683 2/20 0.63
▸ STK10 O94804 2/20 0.63

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1507566 0.92 FBP1 (0.74) EGFRGAKFBP1ALDH1A1MAPT
SCHEMBL1507537 0.91 EGFR (0.69) EGFRGAKFBP1ALDH1A1MAPT
SCHEMBL1507686 0.91 FBP1 (0.64) EGFRGAKFBP1ALDH1A1MAPT
SCHEMBL1507752 0.90 FBP1 (0.60) EGFRGAKFBP1ALDH1A1MAPT
SCHEMBL1507609 0.88 EGFR (0.78) EGFRGAKFBP1ALDH1A1MAPT
SCHEMBL667895 0.84 EGFR (1.00) EGFRGAKFBP1ALDH1A1MAPT
SCHEMBL13882737 0.84 EGFR (0.84) EGFRGAKFBP1ALDH1A1MAPT
Hydrochloric Acid SCHEMBL1507455 0.83 EGFR (0.98) EGFRGAKFBP1ALDH1A1MAPT
SCHEMBL1507611 0.83 FBP1 (0.71) EGFRGAKFBP1ALDH1A1MAPT
SCHEMBL1507535 0.83 EGFR (0.70) EGFRGAKFBP1ALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160303127-A1 COMBINATION THERAPY WITH C-MET AND EGFR ANTAGONISTS GENENTECH INC (US) 2016-10-20 — — US claimed
US-20150086545-A1 COMBINATION THERAPY OF HER EXPRESSING TUMORS GENENTECH, INC. (US) 2015-03-26 — — US claimed
US-20150056207-A1 COMBINATION THERAPY WITH C-MET AND EGFR ANTAGONISTS GENENTECH INC (US) 2015-02-26 — — US claimed
US-20120251530-A1 COMBINATION THERAPY OF HER EXPRESSING TUMORS SLIWKOWSKI MARK X (US) 2012-10-04 — — US claimed
US-8163287-B2 Combination therapy of her expressing tumors GENENTECH, INC. (US) 2012-04-24 — — US claimed
EP-2344543-A2 TREATMENT METHOD Genentech, Inc. (US) 2011-07-20 — — EP claimed
JP-2011513427-A — — 2011-04-28 — — JP claimed
EP-2295415-A1 Quinazoline derivatives OSI Pharmaceuticals, Inc. (US) 2011-03-16 — — EP claimed
EP-2257293-A2 COMBINATION THERAPY WITH C-MET AND EGFR ANTAGONISTS Genentech, Inc. (US) 2010-12-08 — — EP claimed
WO-2010045345-A2 TREATMENT METHOD GENENTECH, INC. (US) 2010-04-22 — — WO claimed
WO-2009111691-A2 COMBINATION THERAPY WITH C-MET AND EGFR ANTAGONISTS GENENTECH, INC. (US) 2009-09-11 — — WO claimed
US-20090226443-A1 COMBINATION THERAPY WITH C-MET AND EGFR ANTAGONISTS GENENTECH, INC. (US) 2009-09-10 — — US claimed
WO-2007013950-A9 COMBINATION THERAPY OF HER EXPRESSING TUMORS GENENTECH INC (US) 2007-03-29 — — WO claimed
WO-2007013950-A2 COMBINATION THERAPY OF HER EXPRESSING TUMORS GENENTECH, INC. (US) 2007-02-01 — — WO claimed
US-20070020261-A1 Combination therapy of her expressing tumors GENENTECH, INC. 2007-01-25 — — US claimed
EP-0817775-B1 QUINAZOLINE DERIVATIVES PFIZER (US) 2001-09-12 — — EP claimed
EP-1110953-A1 Quinazoline derivatives PFIZER INC. (US) 2001-06-27 — — EP claimed
US-5747498-A Alkynyl and azido-substituted 4-anilinoquinazolines PFIZER INC. (US) 1998-05-05 — — US claimed
EP-0817775-A1 QUINAZOLINE DERIVATIVES PFIZER INC. (US) 1998-01-14 — — EP claimed
WO-1996030347-A1 QUINAZOLINE DERIVATIVES PFIZER INC. (US) 1996-10-03 — — WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150086545-A1 COMBINATION THERAPY OF HER EXPRESSING TUMORS ERBB2, EGFR, ERBB3 EGFR 2/4885GAK 1055/4885FBP1 2318/4885
US-20070020261-A1 Combination therapy of her expressing tumors ERBB2, EGFR, ERBB3 EGFR 2/4885GAK 1055/4885FBP1 2318/4885
US-20090226443-A1 COMBINATION THERAPY WITH C-MET AND EGFR ANTAGONISTS MET, EGFR, ERBB2 EGFR 2/4885GAK 1255/4885FBP1 3214/4885
US-20160303127-A1 COMBINATION THERAPY WITH C-MET AND EGFR ANTAGONISTS MET, EGFR, ERBB2 EGFR 2/4885GAK 1255/4885FBP1 3214/4885
US-20150056207-A1 COMBINATION THERAPY WITH C-MET AND EGFR ANTAGONISTS MET, EGFR, ERBB2 EGFR 2/4885GAK 1255/4885FBP1 3214/4885
US-20120251530-A1 COMBINATION THERAPY OF HER EXPRESSING TUMORS ERBB2, EGFR, ERBB3 EGFR 2/4885GAK 1055/4885FBP1 2318/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.